Bleselumab

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameBleselumab
Drug Alias Name4D-11ASKP-1240
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationPsoriasis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kogyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Kirin Co LtdAstellas Pharma IncAstellas Pharma Global Development Inc +[4] 
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationRejection of renal transplantationPsoriasis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A